Abelacimab(Abelacimab) - 药物靶点：FXIa_在研适应症：心房颤动，全身性栓塞，脑卒中_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Ablacacimab、MAA-868、NOV-12

+ [3]

靶点

FXIa

作用方式

抑制剂

作用机制

factor XIa抑制剂(凝血因子XIa抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Anthos Therapeutics, Inc.

MorphoSys AG

+ [3]

非在研机构

Novartis Pharmaceuticals Corp.

权益机构

Novartis AG

Anthos Therapeutics, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 13004871H

来源: *****

Sequence Code 13004906L

来源: *****

关联

9

项与 Abelacimab 相关的临床试验

NCT05712200

/ Recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

开始日期2022-12-27

申办/合作机构

Anthos Therapeutics, Inc.

[+1]

NCT05171075

/ Terminated临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

开始日期2022-09-27

申办/合作机构

Anthos Therapeutics, Inc.

[+1]

NCT05171049

/ Terminated临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

开始日期2022-05-05

申办/合作机构

Anthos Therapeutics, Inc.

[+1]

100 项与 Abelacimab 相关的临床结果

登录后查看更多信息

100 项与 Abelacimab 相关的转化医学

登录后查看更多信息

100 项与 Abelacimab 相关的专利（医药）

登录后查看更多信息

33

项与 Abelacimab 相关的文献（医药）

2025-11-01·JAMA Cardiology

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function

Article

作者: Bloomfield, Dan ; Wojakowski, Wojciech ; Murphy, Sabina A. ; Goodman, Shaun G. ; Morrow, David A. ; Kiss, Robert G. ; Patel, Siddharth M. ; Weitz, Jeffrey I. ; Parkar, Sanobar ; Ruff, Christian T. ; Giugliano, Robert P. ; Sabatine, Marc S. ; Joung, Boyoung ; Chen, Shih-Ann ; Goodrich, Erica L. ; Hug, Bruce

Importance:

Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with higher rates of bleeding with anticoagulation. In the AZALEA-TIMI 71 randomized clinical trial, abelacimab, a novel factor XI inhibitor, reduced rates of major or clinically relevant nonmajor (CRNM) bleeding compared with rivaroxaban in patients with AF.

Objective:

To examine the safety of abelacimab vs rivaroxaban across a range of kidney function.

Design, Setting, and Participants:

The AZALEA-TIMI 71 study randomized patients with AF to 1 of 2 abelacimab doses (150 mg or 90 mg monthly) or to rivaroxaban, with stratification by creatinine clearance (CrCl). Patients with CrCl less than 15 mL/min or receiving dialysis were excluded. This secondary analysis of AZALEA-TIMI 71 examines outcomes by randomized treatment and CrCl at randomization.

Intervention:

Patients randomized to rivaroxaban with a CrCl greater than 50 mL/min received rivaroxaban, 20 mg, daily, and those with a CrCl of 50 mL/min or less received rivaroxaban, 15 mg, daily. Patients randomized to abelacimab received the assigned dose irrespective of CrCl.

Main Outcomes and Measure:

The primary outcome was major bleeding or CRNM bleeding.

Results:

Among 1284 patients, median (IQR) age was 74 (69-78) years and 572 patients (44.5%) were female. Median (IQR) CrCl was 71 (54-90) mL/min, with 264 patients (20.6%) having a CrCl of 50 mL/min or less. In the rivaroxaban group, patients with CrCl of 50 mL/min or less experienced higher rates of major or CRNM bleeding compared with those with CrCl greater than 50 mL/min despite dose reduction (incidence rates, 13.6 vs 7.0 per 100 person-years). Abelacimab reduced major or CRNM bleeding vs rivaroxaban irrespective of CrCl (CrCl ≤50 mL/min: hazard ratio [HR], 0.26; 95% CI, 0.12-0.54; &gt;50 mL/min: HR, 0.40; 95% CI, 0.26-0.62; P value for interaction = .33), with absolute risk reductions of 10.1 vs 4.2 per 100 person-years in those with CrCl of 50 mL/min or less vs greater than 50 mL/min, respectively ( P value for interaction = .09). This risk reduction was consistent for major bleeding alone and for a broader composite inclusive of major, CRNM, and minor bleeding. Results were similar when comparing the individual abelacimab doses to rivaroxaban.

Conclusions and Relevance:

In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in AF.

2025-11-01·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Factor XI/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation with stroke risk: a GRADE-assessed meta-analysis of randomized controlled trials

Review

作者: Aldemerdash, Mohamed A ; Hemmeda, Lina ; Emara, Mohamed ; Murad, Mohamed R ; Ellebedy, Mohamed ; Elgendy, Mohamed S ; Gadelmawla, Ahmed Farid ; Mohammed, Ahmed Abduljalil ; Emara, Ahmed ; Abdelazeem, Basel

Direct oral anticoagulants (DOACs) prevent stroke in atrial fibrillation (AF) but are associated with an increased risk of major bleeding. Factors XI/XIa (FXI) inhibitors, such as Abelacimab and Asundexian, offer a promising alternative. This meta-analysis compares FXI/XIa inhibitors' safety and efficacy versus DOACs in AF with stroke risk. A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed from PubMed, Scopus, Cochrane, and Web of Science up to March 2025. The analysis presented risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI) using RevMan v5.4. Three RCTs involving 16,852 patients were included, with 8777 (52.1%) receiving FXI inhibitors which significantly reduced the risk of major bleeding (0.4% vs. 1.0%, RR 0.31, 95% CI 0.21-0.46, p < 0.00001) and minor bleeding (3.3% vs. 4.7%, RR 0.66, 95% CI 0.47-0.93; p = 0.02) compared with DOACs. However, FXI inhibitors were associated with a significantly higher risk of stroke or systemic embolism (1.4% vs. 0.4%, RR 3.17, 95% CI 2.18-4.62, p < 0.00001). Safety outcomes showed no difference in total adverse events (AEs) (p = 0.91), serious AEs (p = 0.4768), and all-cause mortality (p = 0.15). In conclusion, current evidence suggests that FXI inhibitors significantly reduce major and minor bleeding events in AF patients at risk of thromboembolic disorders compared to DOACs. However, they are associated with a significant increase in stroke or systemic embolism risk. Further large-scale RCTs are needed to confirm these findings.

2025-10-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study

Article

作者: Lecompte, Thomas ; Mullier, François ; Douxfils, Jonathan ; Thonon, Henri ; Vassart, Julie ; Lessire, Sarah ; Gouin-Thibault, Isabelle ; Hardy, Michael

BACKGROUND:

Invasive endovascular procedures often require anticoagulation to prevent device-associated thrombosis. High doses of unfractionated heparin (UFH) are the gold standard. The efficacy of factor (F)XII(a) and FXI(a) inhibitors remains unexplored.

OBJECTIVES:

We aimed to investigate, using a validated in vitro model of catheter-initiated thrombin generation (TG) in platelet-rich plasma (PRP), the effects of garadacimab, abelacimab, asundexian, and milvexian and of commonly used anticoagulants apixaban, dabigatran, fondaparinux and heparins (enoxaparin and UFH).

METHODS:

Anticoagulants were added to PRP at 6 concentrations and effects compared with UFH as a reference. The impact of adding anticoagulants into collection tubes before most preanalytical contact activation was also assessed. Concentrations achieving a 50% reduction in TG peak height (PH) were determined (IC₅₀).

RESULTS:

All anticoagulants prolonged lag time (LT) and reduced PH and endogenous thrombin potential, albeit to varying extents. UFH was the only anticoagulant able to suppress TG at clinically achieved concentrations (1 U/mL). The following IC₅₀ were found: milvexian, 2400 ng/mL; apixaban and dabigatran, 175 ng/mL; fondaparinux, 2.4 μg/mL; enoxaparin, 0.5 U/mL; and UFH, 0.25 U/mL. Asundexian up to 5000 ng/mL failed to reduce TG PH by 50%. Adding garadacimab and abelacimab to collection tubes resulted in greater efficacy than when added to PRP: LT increased by 89% and 32%, respectively; IC₅₀ were 25 and 12.5 μg/mL, respectively.

CONCLUSION:

Heparins were by far the most effective anticoagulants in our in vitro model. FXIIa and FXI(a) inhibitors did not adequately prevent coagulation on the studied artificial surface. Direct oral anticoagulants and fondaparinux showed limited efficacy, aligning with clinical observations.

215

项与 Abelacimab 相关的新闻（医药）

2026-04-23

·精准药物

刚刚！诺华终止1个III期临床，百济神州暂停EGFR降解剂I期临床

百济神州EGFR降解剂一项临床试验暂停近日，据外媒报道，百济神州（BeOne）已于上周将针对晚期或转移性EGFR突变非小细胞肺癌患者的BG-60366Ⅰ期临床试验在clinicaltrials.gov网站上被标注为“研究进行中、不再招募”；该试验入组在33例时即暂停，远低于最初计划的93例目标。当被问及这一调整时，BeOne发言人表示，该研究“已暂停，我们正在评估现有研究数据”。尽管公司尚未正式确认终止研发，但BG-60366的前景愈发不明朗，为这一在研资产的未来蒙上阴影。目前尚无迹象表明，最新数据中究竟是何种情况促使BeOne暂停试验，但不排除出现不良事件的可能性。诺华终止一项临床III期试验近日，诺华（Novartis）宣布停止其抗凝血抗体药物abelacimab针对癌症相关血栓（CAT）的开发工作。这项始于2022年、招募了1150名患者的第3期临床试验在数据审查后被提前终止，原因是该药物未能击败百时美施贵宝（BMS）和辉瑞的重磅抗凝药Eliquis。受此影响，诺华还同时叫停了另一项比较abelacimab与辉瑞Fragmin在胃肠道或泌尿生殖系统癌症相关静脉血栓栓塞患者中疗效的第3期试验。尽管在2026年遭遇了这一重大挫折，诺华并未完全放弃该药物的开发，abelacimab目前仍在继续进行其首要适应症——心房颤动（AFib）的第3期临床试验，公司计划在2028年提交该适应症的上市批准申请。肿瘤药物筛选服务声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

临床3期临床2期

2026-04-22

·新药猎人笔记

31亿美元回购自家NewCo的FXI抗体遭遇开发挫折

诺华（Novartis）近日宣布，基于临床试验中观察到的"疗效较差"（inferior efficacy），公司已终止其FXI抑制剂abelacimab在癌症相关血栓（Cancer-Associated Thrombosis, CAT）领域的两项III期临床研究——ASTER与MAGNOLIA。这一决定距离诺华以9.25亿美元预付款、最高31亿美元总价将abelacimab重新收回自有管线仅过去数月，标志着这桩曾被寄予厚望的回购交易遭遇重大挫折。不过，诺华明确表示，将继续推进abelacimab在核心适应症心房颤动（AF）领域的III期项目LILAC-TIMI 76。从NewCo到回购 Abelacimab的曲折之路 Abelacimab（MAA868）是一款靶向凝血因子XI（FXI）及其活化形式FXIa的全人源单克隆抗体，其作用机制在于模拟天然FXI缺乏状态，在保留止血功能的同时抑制病理性血栓形成。该药物最初由诺华自主研发，但于2019年被授权给Anthos Therapeutics——一家由Blackstone Life Sciences与诺华共同创立、获得2.5亿美元启动资金的企业——进行后续临床开发。 2025年2月，诺华宣布以最高31亿美元收购Anthos，其中 upfront 支付9.25亿美元，此举将abelacimab重新纳入诺华心血管-肾脏-代谢（CRM）管线。交易于2025年4月正式完成。彼时，诺华全球CRM开发负责人David Soergel曾评价abelacimab为"潜在first-in-class药物"，认为其有望提供比现有标准治疗更有效、更安全的抗凝方案。 CAT领域"折戟"： ASTER与MAGNOLIA的临床设计被终止的ASTER（NCT05171049）与MAGNOLIA（NCT05171075）试验是abelacimab在CAT领域的关键III期项目，两项研究合计计划入组约2,700名患者，覆盖全球220个中心、20余个国家，堪称迄今CAT领域规模最大的抗凝剂临床项目。具体而言，ASTER试验旨在评估abelacimab（首日静脉给药150mg，之后每月皮下注射维持）对比阿哌沙班（apixaban）在适合接受直接口服抗凝药（DOAC）治疗的癌症患者中的疗效与安全性，主要终点为6个月内静脉血栓栓塞（VTE）复发时间。而MAGNOLIA试验则针对消化道（GI）或泌尿生殖道（GU）肿瘤这类DOAC治疗禁忌的高出血风险患者，比较abelacimab与低分子肝素达肝素（dalteparin）的疗效。两项研究的主要终点均为VTE复发时间的非劣效性，次要终点则聚焦于大出血及临床相关非大出血（CRNM）的优效性。根据ClinicalTrials.gov最新状态，ASTER和MAGNOLIA试验已被标注为"终止"（Terminated），终止原因为"申办方决定"（Sponsor decision）。 FXI抑制剂的集体困境 Abelacimab在CAT领域的受挫并非FXI抑制剂类别的孤立事件。此前，拜耳（Bayer）的FXIa小分子抑制剂asundexian在III期OCEANIC-AF试验中因疗效不如阿哌沙班而被提前终止；BMS与强生合作的milvexian亦曾在卒中预防的II期研究中未能展现明确的剂量反应关系。值得注意的是，abelacimab在II期AZALEA-TIMI 71研究中曾展现出令人瞩目的安全性信号：与利伐沙班（rivaroxaban）相比，150mg剂量abelacimab可降低67%的主要出血风险及89%的胃肠道出血风险，该试验因"压倒性的临床获益"被独立数据监测委员会建议提前终止。然而，该研究以安全性为主要终点，且卒中或系统性栓塞事件在数值上略高于利伐沙班组（1.21 vs 0.83事件/100人年），因样本量限制未能得出确定性疗效结论。这一疗效层面的"隐忧"或许为此次CAT III期试验的失利埋下了伏笔。房颤适应症成为"全村的希望" 尽管CAT适应症遭遇重挫，诺华仍选择保留abelacimab在房颤卒中预防领域的III期项目LILAC-TIMI 76。该试验针对被认为"不适合口服抗凝药"的高危房颤患者，采用abelacimab对比安慰剂的设计，预计于2026年下半年完成。从商业逻辑看，这一决策不难理解。房颤是全球数千万患者人群的大适应症，而CAT虽为临床未满足需求强烈的细分赛道，但患者群体相对有限。对诺华而言，若LILAC-TIMI 76能够成功验证abelacimab在房颤患者中的疗效与安全性优势，该药物仍有望在2027年前后提交监管申请，成为新一代抗凝治疗的潜在领导者。结束语： FXI抑制剂能否真正实现"疗效与出血风险的脱钩"，仍需更多硬终点数据验证。在拜耳、BMS/强生相继受挫之后，诺华能否凭借abelacimab在房颤领域扳回一城，将成为决定这31亿美元交易最终回报的关键变量。

2026-04-22

·医药速览

诺华大瓜！终止临床III期试验

诺华（Novartis）宣布停止其抗凝血抗体药物abelacimab针对癌症相关血栓（CAT）的开发工作。这项始于2022年、招募了1150名患者的第3期临床试验在数据审查后被提前终止，原因是该药物未能击败百时美施贵宝（BMS）和辉瑞的重磅抗凝药Eliquis。受此影响，诺华还同时叫停了另一项比较abelacimab与辉瑞Fragmin在胃肠道或泌尿生殖系统癌症相关静脉血栓栓塞患者中疗效的第3期试验。尽管在2026年遭遇了这一重大挫折，诺华并未完全放弃该药物的开发，abelacimab目前仍在继续进行其首要适应症——心房颤动（AFib）的第3期临床试验，公司计划在2028年提交该适应症的上市批准申请。这项房颤试验招募了1900名不适合使用Eliquis和Xarelto等口服抗凝药的患者，并将其与安慰剂进行对比。回顾该药物的发展历程，诺华曾在2019年与黑石共同投资2.5亿美元剥离创立了Anthos Therapeutics，专门开发这款凝血因子XI/XIa抑制剂，旨在实现防止血栓形成的同时不增加出血风险。在第2期试验中，abelacimab显示出比依诺肝素降低80%静脉血栓栓塞的优异疗效，且出血率低于旧款抗凝药Xarelto，这促使诺华在2025年2月斥资9.25亿美元预付款（以及高达21.5亿美元的潜在里程碑付款）重新收购了Anthos，并将预计于2026年完成的三项第3期试验的控制权收回。诺华的曲折经历折射出了整个凝血因子XI抑制剂赛道激烈的竞争与巨大的开发风险，各大药企都试图在这个即将面临非维生素K口服抗凝仿制药竞争的市场中分一杯羹。就在几个月前的2025年11月14日，百时美施贵宝和强生（J&J）也因疗效不佳，提前终止了其凝血因子XIa抑制剂milvexian针对急性冠状动脉综合征（ACS）的试验，独立数据监测委员会认定该试验无法在常规抗血小板治疗的基础上达到主要疗效终点，导致BMS股价在盘前下跌了6%。这项原本计划招募1.6万名患者并在2026年底结束的试验宣告失败，对ACS患者是一个沉重的打击，因为如果试验成功，milvexian本有望成为首个获批用于ACS的该类药物。不过，由于中期分析未发现新的安全问题，BMS和强生仍在继续推进milvexian在房颤和继发性卒中预防（SSP）方面试验。在同一赛道上，拜耳（Bayer）的凝血因子XIa抑制剂asundexian曾因患者发生致命心血管事件的比例是Eliquis的两倍，而在2023年被提前终止了房颤的试验。然而，拜耳随后在另一项试验中成功证明asundexian能够显著降低中风风险，这为该德国药企在2026年提交批准申请奠定了基础。推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。 ©2021 医药速览保留所有权利往期链接 “小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学| 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普|医药前沿笔记 PROTAC技术| 抗体药物| 抗体药物偶联-ADC 核酸疫苗 | CAR技术| 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群请扫描上方二维码，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送 ①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

临床3期并购临床2期

100 项与 Abelacimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性栓塞	临床3期	美国	Lonza AG	2022-12-27
全身性栓塞	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	日本	Lonza AG	2022-12-27
全身性栓塞	临床3期	日本	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	加拿大	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	临床2期	脑卒中 \| 心房颤动	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	顧積齋鹽襯齋繭壓鬱齋 = 鹽壓艱憲憲蓋繭醖蓋醖夢顧艱鏇遞鏇鬱鑰膚構 (製廠憲壓艱築網衊獵築, 衊鑰鹽獵積獵襯鑰壓蓋 ~ 壓網選網鹹鑰糧壓壓鹽) 更多	-	2025-07-30
				Abelacimab (Abelacimab 150 mg (MAA868))	顧積齋鹽襯齋繭壓鬱齋 = 製窪選網艱顧構醖窪鑰夢顧艱鏇遞鏇鬱鑰膚構 (製廠憲壓艱築網衊獵築, 遞衊網襯範簾艱夢襯簾 ~ 鬱憲衊鬱糧膚積淵築夢) 更多
NCT04755283 (AZALEA-TIMI 71, Company_Website) 人工标引	临床2期	出血 \| 心房颤动	-	abelacimab (≥75 years)	憲餘獵齋顧繭餘醖憲鹽(鹽蓋壓製鹹構製齋蓋網) = 製鹽鏇積憲齋簾鏇鹹鏇網鏇窪築膚壓夢憲淵鑰 (糧廠齋繭網艱遞繭廠餘 )	积极	2025-04-08
				abelacimab (＜75 years)	憲餘獵齋顧繭餘醖憲鹽(鹽蓋壓製鹹構製齋蓋網) = 餘積壓醖壓糧醖夢淵鬱網鏇窪築膚壓夢憲淵鑰 (糧廠齋繭網艱遞繭廠餘 )
NCT04755283 (AZALEA-TIMI 71, Pubmed) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mgAbelacimab 150 mg	鹹築蓋鬱鏇遞窪鬱廠鏇(鏇選襯積壓觸觸衊夢餘) = 蓋襯夢淵觸壓築齋壓襯願製齋繭艱艱鬱選繭簾 (蓋範憲醖積構製壓餘艱 )	积极	2025-01-23
				AbelacimabAbelacimab 90 mg	鹹築蓋鬱鏇遞窪鬱廠鏇(鏇選襯積壓觸觸衊夢餘) = 衊廠積鑰獵糧範艱獵艱願製齋繭艱艱鬱選繭簾 (蓋範憲醖積構製壓餘艱 )
NCT04755283 (AZALEA-TIMI 71, GlobeNewswire) 人工标引	临床2期	血栓形成	-	Abelacimab 150 mg	壓襯鏇範積廠齋衊觸鏇(鹹蓋遞憲憲窪夢範獵選) = 窪鏇鹹網顧壓選糧積繭觸築範窪遞構築襯醖壓 (壓築夢簾衊構艱淵鑰觸 )	积极	2024-11-16
				Rivaroxaban	壓襯鏇範積廠齋衊觸鏇(鹹蓋遞憲憲窪夢範獵選) = 構壓膚廠觸構繭選淵網觸築範窪遞構築襯醖壓 (壓築夢簾衊構艱淵鑰觸 )
NCT04755283 (AZALEA-TIMI 71, PipelineReview) 人工标引	N/A	心房颤动	1,287	abelacimab 150 mg	鏇構鬱選鬱簾憲蓋鹹鹽(夢築鬱範願選構獵襯鑰) = 衊範獵糧鑰廠窪簾淵餘鏇壓齋範淵衊簾壓鬱廠 (廠鏇鏇餘製餘選構鹽範 ) 更多	积极	2023-11-13
				rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71 , Corporate Publications) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mg	築選淵構製顧窪衊糧選(窪築構顧鹽繭獵簾顧餘) = 壓齋鏇遞憲淵憲窪艱鏇壓鹹繭觸糧艱遞餘鑰壓 (餘構鏇膚餘蓋蓋蓋衊鬱 ) 更多	优效	2023-11-12
				Rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71, Biospace) 人工标引	临床2期	心房颤动	1,287	Abelacimab	鑰鏇獵襯鏇顧鹽顧夢夢(鏇夢遞膚鹽廠積製淵餘) = met 簾壓鹹蓋簾網製夢壓淵 (窪鏇顧餘艱蓋淵膚襯齋 ) 达到	积极	2023-09-18
				Rivaroxaban
NCT04213807 (CTgov)	临床2期	心房颤动	28	Placebo	鏇選齋壓醖膚衊鹹製膚 = 齋齋鹹選齋鹽憲蓋鹹憲醖積願衊獵齋糧醖窪糧 (鹽鏇鹽範觸鬱蓋窪壓範, 齋齋淵積鑰觸網餘範壓 ~ 觸餘繭鏇艱選齋淵積鏇) 更多	-	2021-12-07
EUCTR2019-003756-37-BG (ANT-005 TKA, ISTH2021 \| Company_Website) 人工标引	临床2期	静脉血栓栓塞	412	30mg abelacimab	夢選願壓淵糧觸鬱構鹽(鏇遞製遞範構鹽範顧醖) = 簾獵蓋窪觸選製糧顧簾觸醖壓願艱簾願鹽範襯 (選製製願淵簾鹹積願窪 ) 更多	积极	2021-07-17
				75mg abelacimab	夢選願壓淵糧觸鬱構鹽(鏇遞製遞範構鹽範顧醖) = 餘廠製窪醖廠膚範壓壓觸醖壓願艱簾願鹽範襯 (選製製願淵簾鹹積願窪 ) 更多